P&F Products & Features GmbH Enhances Heart Solutions with AVVie GmbH Acquisition

P&F Products & Features GmbH Strengthens Portfolio with AVVie Acquisition

In a significant move to strengthen its product offerings, P&F Products & Features GmbH (P&F) has announced the acquisition of AVVie GmbH. AVVie was founded by renowned cardiac surgeon, Professor Werner Mohl, and has developed groundbreaking technology aimed at addressing structural heart diseases, specifically through their innovative AngelValve™ augmentation system.

AngelValve™ stands out as a next-generation transcatheter platform designed to tackle the pressing needs of mitral valve disease treatments. This device is crucial for patients who experience mitral regurgitation, a condition affecting millions across Europe and the United States. Currently, it is estimated that more than 13 million individuals suffer from this condition, yet less than 5% receive the necessary treatment, primarily due to limitations in available methods. P&F is committed to bridging this treatment gap and improving the quality of life for these patients.

By merging AVVie’s innovative research and development infrastructure with P&F's global reach and expertise in product development, clinical, and regulatory affairs, both companies expect to accelerate innovation in heart therapy solutions and significantly reduce product development timelines.

Dr. Katharina Kiss, CEO of P&F, stated, “The acquisition of AVVie reflects our unwavering commitment to advancing breakthrough structural heart disease therapies. By combining AVVie’s engineering prowess with P&F’s clinical research capabilities and regulatory expertise, we are ideally positioned to promote the AngelValve™ platform and provide meaningful innovations to clinicians and patients worldwide.”

Siegfried Einhellig, P&F's Chief Operating Officer and President, added, “This combination unites exceptional engineering talent with proven development capabilities. We are excited to turn this innovation into a successful treatment option.”

The financial specifics of this acquisition have not been disclosed, but it marks a critical milestone for P&F as they aim to solidify their leadership in the field of structural heart therapy. With headquarters in Vienna, Austria, P&F Products & Features GmbH has over 25 years of experience in developing innovative cardiovascular solutions, operating in approximately 70 countries. Their commitment to enhancing patient care through quality products positions them as a significant player in the medical technology landscape.

In a sector where timely interventions can translate into life-saving solutions, P&F’s prospect of introducing the AngelValve™ system offers hope to patients with structural heart diseases. As the company integrates the advanced technologies from AVVie, it prepares to ensure that millions more receive timely and effective treatment. As developments unfold, the healthcare community will undoubtedly keep a close eye on P&F’s next steps in the realm of cardiac care.

For more information on P&F’s products and their ongoing innovations, visit their website at productsandfeatures.com.